MindWalk vs Immutep
HYFT and IMMP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HYFT and IMMP compare
Immutep grew revenue faster over the last twelve months (134% versus 43.4% for MindWalk).
Immutep scores higher on the StockData Score (8 against 7 for MindWalk), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HYFT | IMMP |
|---|---|---|
| Size and price | ||
| Share price | $0.990 | $3.48 |
| Change, 1 year | −44.7% | −90.3% |
| Change, 5 years | −82.1% | −95.4% |
| Beta (5Y) | 1.36 | 1.67 |
| Employees | – | 46 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 43.4% | 134% (better) |
| Revenue growth, 5Y average | −2.8% | 43.5% (better) |
| Profitability | ||
| Gross margin | 60.8% | – |
| Net margin | – | −328% |
| FCF margin | −76.9% (better) | −230% |
| Return on equity | – | −77.3% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 1.84 | 5.69 (better) |
| Piotroski F-score | – | 2 |
| Ownership | ||
| Held by institutions | 9.3% | – |
| Held by insiders | 0.00% | 0.89% |
Go deeper
- HYFT stock overview
- HYFT income statement
- HYFT valuation and score
- IMMP stock overview
- IMMP income statement
- IMMP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.